Clinical efficacy of Velac®, a new tretinoin and clindamycin phosphate gel in acne vulgaris

Journal of the European Academy of Dermatology and Venereology

Volumn 11, Issue SUPPL. 1, 1998, Pages

  Cambazard, F ^a  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

Acne; Clindamycin phosphate; Tretinoin; Velac

Indexed keywords

ABERELA; CLINDAMYCIN; CLINDAMYCIN PHOSPHATE; CLINDAMYCIN PLUS RETINOIC ACID; RETINOIC ACID; UNCLASSIFIED DRUG;

ACNE VULGARIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG FORMULATION; DRUG MIXTURE; DRUG SAFETY; HUMAN; INFLAMMATION; IRRITANT DERMATITIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION;

EID: 0032438643     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.1998.tb00903.x     Document Type: Conference Paper

References (16)

1. Ebling FJG, Cunliffe WJ. Disorders of the sebaceous glands. In: Champion RH, Burton JL, Ebling FJG, editors. Textbook of Dermatology. 5th ed. Oxford-London: Blackwell, 1993:1699-1744.
2. Sykes Jr. NL, Webster GF. Acne. A review of optimum treatment. Drugs 1994;48:59-70.
3. Weiss JS. Current options for the topical treatment of acne vulgaris. Pediat Dermatol 1997;14:480-488.
4. Richter JR, Bousema MT, De Boulle KLVM, Degreef HJ, Poli F. Efficacy of a fixed clindamycin phosphate 1.2%, tretinoin 0.025% gel formulation (Velac®) in the topical control of facial acne lesions. J Dermatol Treat 1998;9:81-90.
5. Richter JR, Förström LR, Kiistala UO, Jung EG. Efficacy of the fixed clindamycin phosphate 1.2% tretinoin 0.025% gel formulation (Velac®) and a proprietary tretinoin 0.025% gel formulation (Aberela®) in the topical control of facial acne lesions. J Eur Acad Dermatol Venereol 1998, in press.
6. Cook CH, Centner RL, Michaels SE. An acne grading method using photographic standards. Arch Dermatol 1979; 115:571-575.
7. Allen BS, Graham Smith J. Various parameters for grading acne vulgaris. Arch Dermatol 1982;118:23-25.
8. Wilkinson JD, Rycroft RJG. Contact Dermatitis. In: Rook A, Wilkinson DS, Ebling FJG, Champion RH, Burton RL, editors. Textbook of Dermatology, part 1, 4th ed. Oxford-London: Blackwell, 1986:435-532.
9. Double blind randomized pilot study to compare once daily clindamycin/tretinoin gel (1% clindamycin; 0.025% tretinoin) with once daily Aberela® gel (0.025% tretinoin) in patients with moderate to severe acne vulgaris. Data on file Yamanouchi Europe B.V. (Report No. 555).
10. Double blind randomized study to compare once daily clindamycin/tretinoin gel (1% clindamycin; 0.025% tretinoin) with once daily Aberela® gel (0.025% tretinoin) in patients with acne vulgaris. Data on file Yamanouchi Europe B.V. (Report No. 588).
11. Double blind randomized study to compare once daily clindamycin/tretinoin gel (1% clindamycin; 0.025% tretinoin) with once daily tretinoin gel (0.025% tretinoin) in patients with acne vulgaris. Data on file Yamanouchi Europe B.V. (Report No. 587).
12. Single blind randomized study to compare once daily clindamycin/tretinoin gel (1% clindamycin; 0.025% tretinoin) with once daily clindamycin gel (1% clindamycin) in patients with acne vulgaris. Data on file Yamanouchi Europe B.V. (Report No. 586).
13. Single blind randomized study to compare once daily Velac® gel (1% clindamycin; 0.025% tretinoin) with twice daily Dalacin T® lotion (1% clindamycin) in patients with moderate to severe acne vulgaris. Data on file Yamanouchi Europe B.V. (Report No. 633).
14. Single blind randomized study to compare once daily Velac® gel (1% clindamycin; 0.025% tretinoin) with twice daily Dalacin T® lotion (1% clindamycin) in patients with moderate to severe acne vulgaris. Data on file Yamanouchi Europe B.V. (Report No. 672).
15. Twenty one day cumulative irritancy assay. Data on file Yamanouchi Europe B.V. (Report HIM-94-YI-I).
16. Bergfeld WF. Topical retinoids in the management of acne vulgaris. J Drug Dev Clin Pract 1996;8:151-160.